AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca intangible amortisation charged to R&D expense ($M) ($M)
Form 20-F Note 10 — Intangible Assets (Inline XBRL)
Latest, FY2025
47
Period ended Dec 31, 2025
Change on a year earlier
+88.0%
25 in FY2024
History
7 years
Since FY2019
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Intangible amortisation charged to R&D expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 47 | +88.0% | Form 20-F FY2025 Annual Report ↗ |
| FY2024 | Dec 31, 2024 | 25 | -10.7% | Form 20-F FY2025 Annual Report ↗ |
| FY2023 | Dec 31, 2023 | 28 | -6.7% | Form 20-F FY2025 Annual Report ↗ |
| FY2022 | Dec 31, 2022 | 30 | -9.1% | Form 20-F FY2024 Annual Report ↗ |
| FY2021 | Dec 31, 2021 | 33 | +13.8% | Form 20-F FY2023 Annual Report ↗ |
| FY2020 | Dec 31, 2020 | 29 | 0.0% | Form 20-F FY2023 Annual Report ↗ |
| FY2019 | Dec 31, 2019 | 29 | – | Form 20-F FY2022 Annual Report ↗ |
Cite this data
StockData. (2026). AstraZeneca Intangible amortisation charged to R&D expense ($M) ($M), annual FY2019–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/intang_amort_rd
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.